Peterson JA, Oblad RV, Mecham JC, Kenealey JD. Resveratrol inhibits plasma membrane Ca
2+-ATPase inducing an increase in cytoplasmic calcium.
Biochem Biophys Rep 2016;
7:253-258. [PMID:
28955914 PMCID:
PMC5613515 DOI:
10.1016/j.bbrep.2016.06.019]
[Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Revised: 06/17/2016] [Accepted: 06/29/2016] [Indexed: 02/03/2023] Open
Abstract
Plasma membrane Ca2+-ATPase (PMCA) plays a vital role in maintaining cytosolic calcium concentration ([Ca2+]i). Given that many diseases have modified PMCA expression and activity, PMCA is an important potential target for therapeutic treatment. This study demonstrates that the non-toxic, naturally-occurring polyphenol resveratrol (RES) induces increases in [Ca2+]i via PMCA inhibition in primary dermal fibroblasts and MDA-MB-231 breast cancer cells. Our results also illustrate that RES and the fluorescent intracellular calcium indicator Fura-2, are compatible for simultaneous use, in contrast to previous studies, which indicated that RES modulates the Fura-2 fluorescence independent of calcium concentration. Because RES has been identified as a PMCA inhibitor, further studies may be conducted to develop more specific PMCA inhibitors from RES derivatives for potential therapeutic use.
Resveratrol induces a rise in [Ca2+]i via plasma membrane Ca2+-ATPase inhibition.
FURA-2 is compatible with resveratrol in measuring [Ca2+]i.
PMCA inhibition is novel to resveratrol among naturally occurring polyphenols.
Collapse